- Home
- AAPG
as 05-30-2025 1:30pm EST
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
| Founded: | 2009 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.2B | IPO Year: | 2025 |
| Target Price: | N/A | AVG Volume (30 days): | 13.6K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.50 - $26.55 | Next Earning Date: | 06-10-2025 |
| Revenue: | $134,352,180 | Revenue Growth: | 341.77% |
| Revenue Growth (this year): | -45.96% | Revenue Growth (next year): | 389.09% |
Latest Ascentage Pharma Group International American Depository Shares News
AAPG Breaking Stock News: Dive into AAPG Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Asian Growth Companies With High Insider Ownership In May 2025
Simply Wall St.
5 days ago
High Growth Tech Stocks in Asia for May 2025
GlobeNewswire
8 days ago
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
Insider Monkey
19 days ago
Is Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now?
GlobeNewswire
a month ago
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
Simply Wall St.
a month ago
High Growth Tech Stocks in Asia to Watch This April 2025
Simply Wall St.
a month ago
Asian Growth Companies With High Insider Ownership
GlobeNewswire
a month ago
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
Compare AAPG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AAPG Ascentage Pharma Group International American Depository Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.